Univercells became a holding company
This transition should allow all four entities to prosper independently and position themselves for sustainable growth. After a transition period aimed at simplifying its structure, Univercells will limit its activities exclusively to those of a holding company. Its R&D activities and partnerships will be continued by Quantoom Biosciences, while the shared services functions will be phased out or organized by commercial companies.
Walloon biotech Univercells sells its subsidiary Univercells Technologies for 136 million euros
In this context, Univercells has launched a “Renault plan”, namely a collective dismissal procedure at group level. An information and consultation phase will be carried out with staff representatives. This procedure concerns 73 employees across the group (out of a total workforce of around 400 people).
Since its founding in 2013, Univercells has set out to transform the way biotechnology medicines are made so that everyone, everywhere can access them. Using cutting-edge bioprocessing and technologies, the group has created transformative processes and platforms for drug discovery, development and delivery.
